Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Mathias Hänel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Susann Schulze, MD, Song-Yau Wang, MD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali

Blood (2018) 132 (Supplement 1): 83.

https://doi.org/10.1182/blood-2018-99-115790

Published: 2018

Journal Articles

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, M Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schulze, Song-Yau Wang, Michael Cross, PhD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali

Blood (2017) 130 (Supplement 1): 1334.

https://doi.org/10.1182/blood.V130.Suppl_1.1334.1334

Published: 2017

Journal Articles

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, Mathias Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schultze, MD, Song-Yau Wang, MD, Oana Brosteanu, PhD, Dietger Niederwieser, MD

Blood (2015) 126 (23): 1346.

https://doi.org/10.1182/blood.V126.23.1346.1346

Published: 2015

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Nadja Jaekel, MD, Song-Yau Wang, MD, Rainer Krahl, PhD, Karolin Hubert, Susann Schulze, MD, Rayk Stengel, PhD, Melanie Schneider, Martin Roskos, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali, MD

Blood (2015) 126 (23): 2014.

https://doi.org/10.1182/blood.V126.23.2014.2014

Published: 2015

Journal Articles

The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

Haifa Kathrin Al-Ali, MD, Song-Yau Wang, Nadja Jaekel, MD, Anne Koehler, MD, Rainer Krahl, PhD, Karolin Hubert, Mrs, Thoralf Lange, MD, Martin Roskos, PhD, Rayak Stengel, PhD, Ines Kovacs, Mrs, Schwabe Scarlett, Mrs, Karoline Schubert, Kathrin Wildenberger, Melanie Schneider, Mrs, Elisabeth Koehler, Mrs, Dietger Niederwieser, MD

Blood (2014) 124 (21): 1860.

https://doi.org/10.1182/blood.V124.21.1860.1860

Published: 2014

Journal Articles

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

Haifa Kathrin Al-Ali, MD, Karolin Hubert, Mrs, Thoralf Lange, MD, Udo Siebolts, Claudia Wichenhauser, MD, Gopalakrishna Prashanth, MD MRCS, Dietger Niederwieser, MD, Astrid Monecke, MD

Blood (2014) 124 (21): 1836.

https://doi.org/10.1182/blood.V124.21.1836.1836

Published: 2014

Journal Articles

Efficacy and Safety of Deferasirox in Patients with Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation: The CICL670ADE02 Trial

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Kai Lieder, Dr., Stefan Albrecht, PhD, Oliver Leismann, PhD, Karolin Hubert, Mrs, Gesine Bug, Nicolaus Kroeger, MD, Uwe Platzbecker, MD, Michael Stadler, MD, Katherina de Haas, MD, Dietger Niederwieser

Blood (2012) 120 (21): 485.

https://doi.org/10.1182/blood.V120.21.485.485

Published: 2012

NARROW

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

Efficacy and Safety of Deferasirox in Patients with Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation: The CICL670ADE02 Trial

Email alerts

ASH Publications

American Society of Hematology

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

Efficacy and Safety of Deferasirox in Patients with Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation: The CICL670ADE02 Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only